Pentixapharm Holding AG is a clinical-stage biopharmaceutical company based in Berlin, Germany, founded in 2019. The company specializes in developing radiopharmaceuticals, primarily focusing on CXCR4 ligand-based products for both diagnostic and therapeutic applications across various medical conditions, including hematological cancers, solid tumors, cardiovascular issues, endocrine disorders, and inflammatory diseases. The company's business model revolves around theranostics, which integrates diagnostics with therapeutics using radiopharmaceuticals. Its key products include: - **PentixaFor (PT-001):** A Gallium-68-based tracer intended for diagnosing and monitoring various conditions, including hematological and solid tumors, as well as endocrine and immunological disorders. - **PentixaTher (PT-002):** A therapeutic radiopharmaceutical utilizing Yttrium-90 and Lutetium-177 for the treatment of leukemia, currently undergoing Phase 1/2 clinical trials. Pentixapharm is also involved in the development of diagnostic tools for functional adrenal tumors, which are in Phase II studies, and anti-GlycoTarget antibodies designed to treat solid tumors. The company completed its IPO on October 3, 2024, listing on the Prime Standard of the Frankfurt Stock Exchange with the ticker symbol PTP, initially priced at EUR 5.10, resulting in a market capitalization of EUR 126.5 million. As of 2025, Pentixapharm reported revenues of EUR 526,000, a decrease from EUR 2.05 million the previous year, while losses amounted to EUR 16.51 million, up 26.4% from 2024. The company employs approximately 36 staff members and is led by Dr. Dirk Pleimes as Group CEO & CMO and Dr. Erik Merten as CTO & COO.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Pentixapharm Holding AG's offering is currently approved on OTHER. Pentixapharm Holding AG is headquartered in Germany. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Pentixapharm Holding AG.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/pentixapharm" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Pentixapharm Holding AG — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/pentixapharm?theme=light as the src instead.
https://www.discoveripo.com/ipo/pentixapharm/opengraph-image
Pentixapharm Holding AG IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/pentixapharm?utm_source=embed&utm_medium=text&utm_campaign=pentixapharm
Get emailed when Pentixapharm Holding AG's terms, price, or expected date change — no weekly noise, just this company.
Pentixapharm Holding AG is listing on OTHER.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company based in Berlin, Germany, founded in 2019. The company specializes in developing radiopharmaceuticals, primarily focusing on CXCR4 ligand-based products for both diagnostic and therapeutic applications across various medical conditions, including hematological cancers, solid tumors, cardiovascular issues, endocrine disorders, and inflammatory diseases. The company's business model revolves around theranostics, which integrates diagnostics with therapeutics using radiopharmaceuticals. Its key products include: - **PentixaFor (PT-001):** A Gallium-68-based tracer intended for diagnosing and monitoring various conditions, including hematological and solid tumors, as well as endocrine and immunological disorders. - **PentixaTher (PT-002):** A therapeutic radiopharmaceutical utilizing Yttrium-90 and Lutetium-177 for the treatment of leukemia, currently undergoing Phase 1/2 clinical trials. Pentixapharm is also involved in the development of diagnostic tools for functional adrenal tumors, which are in Phase II studies, and anti-GlycoTarget antibodies designed to treat solid tumors. The company completed its IPO on October 3, 2024, listing on the Prime Standard of the Frankfurt Stock Exchange with the ticker symbol PTP, initially priced at EUR 5.10, resulting in a market capitalization of EUR 126.5 million. As of 2025, Pentixapharm reported revenues of EUR 526,000, a decrease from EUR 2.05 million the previous year, while losses amounted to EUR 16.51 million, up 26.4% from 2024. The company employs approximately 36 staff members and is led by Dr. Dirk Pleimes as Group CEO & CMO and Dr. Erik Merten as CTO & COO.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy